

# MVIC Symposium 2024 - Program

| Date  | Wednesday the 16 <sup>th</sup> of October to Thursday the 17 <sup>th</sup> of October 2024 |
|-------|--------------------------------------------------------------------------------------------|
| Time  | Day 1: 08:30-17:40, Day 2: 08:30-13:00                                                     |
| Venue | Auditorium in building Inspira, Medicon Village, Lund, Sweden                              |

# Day 1 - Wednesday 16 October 2024

| 08:30-09:00               | Symposium registration                                                                            |                                                          |
|---------------------------|---------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| 09:00-09:15               | Welcome to MVIC Symposium 2024                                                                    | Lars Asking, MVIC                                        |
| Plenary<br>Chairman: Lars | s Asking                                                                                          |                                                          |
| 09:15-09:55               | Current and future inhalation landscape - diseases, molecules/modalities and new players          | Dr. Gunilla Petersson,<br>Inhaled Delivery<br>Consulting |
| 09:55-10:15               | Advantages and limitations of customizable nebulizer platform for combination product development | Henry Cuevas Brun,<br>HCmed Innovations                  |

#### 10:15-11:00 Coffee and mingle

#### Regulatory science and novel approaches

| Chairman: Dr. | Per Bäckman                                                                                                                |                                              |
|---------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| 11:00-11:30   | The inhaled Biopharmaceutical Classification System – Enablement and potential product development and regulatory insights | Dr. Jayne Hastedt,<br>JDP Pharma             |
| 11:30-12:00   | Optimizing inhaled drug development through in silico trials                                                               | Dr. Maximilian Grill,<br>Ebenbuild           |
| 12:00-12:30   | Human PK-studies with Precise Inhale – regional lung targeting assessment                                                  | Ass. Prof. Per Gerde,<br>Inhalation Sciences |
|               |                                                                                                                            |                                              |

# 12:30-13:45 Lunch and mingle

#### Regulatory science and novel approaches cont.

| Chairman: Dr. | Chairman: Dr. Per Bäckman                                           |                     |  |  |
|---------------|---------------------------------------------------------------------|---------------------|--|--|
| 13:45-14:15   | New guidelines for Inhaled Generic Medicines - implications for the | Dr. Mikael Ekström, |  |  |
|               | industry                                                            | Iconovo             |  |  |

#### **Pharmaceutics**

| Chairman: Adj | i. Prof. Kyrre Thalberg                                              |                                          |
|---------------|----------------------------------------------------------------------|------------------------------------------|
| 14:15-14:35   | In vitro - in vivo correlation of levodopa dry powder for inhalation | Dr. Julia Berends,<br>Univ. of Groningen |
| 14:35-14:55   | Biologics dosing by Dry-powder inhalers                              | Dr. Jaap Wieling,<br>PurelMS             |

Org. no: 556929-8820 VAT no: SE556929882001



#### 14:55-16:05 Coffee and mingle

#### Pharmaceutics cont.

Chairman: Adj. Prof. Kyrre Thalberg

| 0.1.a       |                                                                           |                                     |
|-------------|---------------------------------------------------------------------------|-------------------------------------|
| 16:05-16:35 | Next generation of propellants for pMDIs                                  | Dr. Kellisa Lachacz,<br>AstraZeneca |
| 16:35-17:05 | The role of mechanical properties in DPI carriers - an overlooked subject | Zeredecht Majid,<br>Kiel University |
| 17:05-17:35 | Possibilities using TOF-SIMS in inhaled drug delivery                     | Dr. Peter Sjövall,<br>RISE          |
| 17:35-17:40 | Close and summary                                                         | Lars Asking,<br>MVIC                |

17:45-18:30 Drinks reception 18:30- Symposium dinner

# Day 2 - Thursday 17 October 2024

# Opportunities in inhaled drug delivery

Chairman: Dr. Karin von Wachenfeldt

| 0           |                                                                                                                                   |                                 |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| 08:30-09:00 | Ambition Zero Carbon: CFD-PBBM towards alternative bioequivalence studies for inhalation aerosols with Next Generation Propellant | Dr. Duy Nguyen,<br>AstraZeneca  |
| 09:00-09:30 | Inhalation toxicology of biologics                                                                                                | Dr. Joshua Gregory,<br>Affibody |
| 09:30-09:50 | Intranasal Powder: Process, Formulation and Pre-clinical Characterization                                                         | Dr. Jonas Sävmarker,<br>Orexo   |

# 09:50-10:50 Coffee and mingle

# Opportunities in inhaled drug delivery cont.

Chairman: Dr. Karin von Wachenfeldt

| 10:50-11:20 | Inhaled non-small molecules: Opportunities for innovation and the need for foundational research in inhalation science | Dr. Markus Fridén,<br>AstraZeneca |
|-------------|------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| 11:20-11:50 | Nonclinical development of inhaled biopharmaceuticals, oligonucleotides and gene therapies                             | Dr. Bruce Hamilton,<br>Labcorp    |
| 11:50-12:00 | Closing symposium                                                                                                      | Lars Asking,<br>MVIC              |

# 12:00-13:00 Lunch and mingle

Org. no: 556929-8820 VAT no: SE556929882001